Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
aMSCs for IRI in Kidney Transplant
NCT04388761Phase 1Withdrawn
- Start
- Sep 2020
- Primary completion
- Feb 2024
- Modality
- Stem Cell Therapies
01
Overview
Phase 1, randomised, open-label trial of CSCC_ASC in ischemia-reperfusion injury (IRI) (3 arms). Primary endpoint: Serious Adverse Events at 1 year. Planned start Sep 2020; status: withdrawn.
02
Drugs
CSCC_ASC
03
Conditions
ischemia-reperfusion injury (IRI)
Beyond the preview
Go deeper on NCT04388761.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04388761.